2026 Q2 - tulosraportti
45 päivää sitten
‧28 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenFor those of you who have the energy to read and something we should look out for. For those of you who don't have the energy to read the whole thing can scroll down to my last sentence 😅. This is a small compilation based on ATA, Egetis, et al. if you are interested and it concerns e.g. ATA (stands for American Thyroid Association) and the clinical guidelines that apply to MCT8 deficiency and the use of Tiratricol (Emcitate). When a completely new drug is approved for a rare genetic thyroid disease, it usually happens in the following way in the USA Before a brand new, full-scale "Guideline" has time to be printed, American experts often publish a Consensus Statement or a Clinical Practice Guideline Update in the journal Thyroid. This is done to quickly provide clinicians with guidance on how patients should be screened and dosed. This is one thing we can look out for together. American trade organizations (here ATA is the heaviest player) for both endocrinologists and pharmacists will need to issue guidelines on how lab tests should be interpreted, as tiratricol can interfere with traditional T3 blood tests. Key individuals behind the clinical studies for Emcitate (such as the ReTRIACt study) are prominent American pediatric endocrinologists. These doctors often sit on ATA's committees and push for care to be standardized locally. Emcitate is estimated to be commercially available in the USA within 8 to 10 weeks after approval. Distribution takes place via an exclusive partnership with PANTHERx® Rare, the USA's largest independent specialty pharmacy focused on rare diagnoses. They will handle individualized delivery directly to the families. Emcitate's launch strategy is based on already working closely with pediatric endocrinologists and pediatric neurologists. This means intensive education (Disease Awareness), which in turn usually hurries local hospitals and medical societies to formally write the treatment into their internal care programs. This process is indeed ongoing. What is really interesting here is that Egetis has consciously chosen not to wait for the actual FDA approval to start educating doctors, but has rolled out strategic medical educational efforts in several phases. Egetis has its field team (Medical Science Liaisons – MSLs) fully trained ahead of the launch. They handle the education of staff at hospitals to be trained, regarding dosing and interpretation of lab tests at leading university hospitals and pediatric clinics. They already started two digital platforms last spring. The one directed at patients/families can be viewed here: https://www.lifewithmct8deficiency.com/. Before formal approval in September 2026, tiratricol had already reached over 230 patients in more than 25 countries via so-called Expanded Access Programs (license prescription). Several of the heaviest children's hospitals in the USA have therefore already had patients.. Regarding the future: Epidemiological estimates show that MCT8 deficiency affects approximately 1 in 70,000 boys, meaning that in total there are between 5,000 and 10,000 boys and men in the USA and Europe living with the disease. Since the diagnosis was established as late as 2004, the majority are still undiagnosed, which means Egetis' launch plan has a major focus on finding more of these "hidden" patients via screening at hospitals. Today, over 230 patients are treated globally with Emcitate. The distribution between the USA and the rest of the world looks as follows: Patients in the USA (approx. 50–60 active distributed across Expanded Access Program (EAP): Approximately 40 patients and clinical trials in the ReTRIACt study, approx. 15–19 pieces. From 230 patients globally to between 5000 and 10000 patients is a staggering potential for Egetis and if a potential acquirer knows this and does not have Pareto as an analyst, today's stock prices should be peanuts...... Good evening - tomorrow it continues!
·3 päivää sitten · MuokattuMy FB group in the previous post was set as inactive - now it is active. See the previous post with my ChatGPT chat of 54 pages starting in sep’2025 when I bought the first ones. Remember it IS AI - with all the reservations one must have with it. But it does represent a wonderful computing power, which one then just really needs to fact-check and (not least) reality-check!- ·3 päivää sitten · MuokattuHello - I have an old FB group left over from the happy Corona days - nothing really happens in the group anymore, but now I have just uploaded my 54-page Egetis thread, which starts in September 2025, where I buy the first ones. If you think it's interesting, you can just join - and then just jump out again when you've seen the AI thread. It is generated in a paid ChatGPT - and as always, you should neither use AI nor other people's posts as an investment basis - make your own analyses and ALWAYS fact-check AI answers. I guess I unfortunately can't upload it here - otherwise I would have done it. It is called "Udbytte & Risiko aktier_Balanceret Portefølje"
·3 päivää sittenThen we broke 9 on still high volume, extremely bullish! Exciting to see if it opens up for the next round number....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |
2026 Q2 - tulosraportti
45 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenFor those of you who have the energy to read and something we should look out for. For those of you who don't have the energy to read the whole thing can scroll down to my last sentence 😅. This is a small compilation based on ATA, Egetis, et al. if you are interested and it concerns e.g. ATA (stands for American Thyroid Association) and the clinical guidelines that apply to MCT8 deficiency and the use of Tiratricol (Emcitate). When a completely new drug is approved for a rare genetic thyroid disease, it usually happens in the following way in the USA Before a brand new, full-scale "Guideline" has time to be printed, American experts often publish a Consensus Statement or a Clinical Practice Guideline Update in the journal Thyroid. This is done to quickly provide clinicians with guidance on how patients should be screened and dosed. This is one thing we can look out for together. American trade organizations (here ATA is the heaviest player) for both endocrinologists and pharmacists will need to issue guidelines on how lab tests should be interpreted, as tiratricol can interfere with traditional T3 blood tests. Key individuals behind the clinical studies for Emcitate (such as the ReTRIACt study) are prominent American pediatric endocrinologists. These doctors often sit on ATA's committees and push for care to be standardized locally. Emcitate is estimated to be commercially available in the USA within 8 to 10 weeks after approval. Distribution takes place via an exclusive partnership with PANTHERx® Rare, the USA's largest independent specialty pharmacy focused on rare diagnoses. They will handle individualized delivery directly to the families. Emcitate's launch strategy is based on already working closely with pediatric endocrinologists and pediatric neurologists. This means intensive education (Disease Awareness), which in turn usually hurries local hospitals and medical societies to formally write the treatment into their internal care programs. This process is indeed ongoing. What is really interesting here is that Egetis has consciously chosen not to wait for the actual FDA approval to start educating doctors, but has rolled out strategic medical educational efforts in several phases. Egetis has its field team (Medical Science Liaisons – MSLs) fully trained ahead of the launch. They handle the education of staff at hospitals to be trained, regarding dosing and interpretation of lab tests at leading university hospitals and pediatric clinics. They already started two digital platforms last spring. The one directed at patients/families can be viewed here: https://www.lifewithmct8deficiency.com/. Before formal approval in September 2026, tiratricol had already reached over 230 patients in more than 25 countries via so-called Expanded Access Programs (license prescription). Several of the heaviest children's hospitals in the USA have therefore already had patients.. Regarding the future: Epidemiological estimates show that MCT8 deficiency affects approximately 1 in 70,000 boys, meaning that in total there are between 5,000 and 10,000 boys and men in the USA and Europe living with the disease. Since the diagnosis was established as late as 2004, the majority are still undiagnosed, which means Egetis' launch plan has a major focus on finding more of these "hidden" patients via screening at hospitals. Today, over 230 patients are treated globally with Emcitate. The distribution between the USA and the rest of the world looks as follows: Patients in the USA (approx. 50–60 active distributed across Expanded Access Program (EAP): Approximately 40 patients and clinical trials in the ReTRIACt study, approx. 15–19 pieces. From 230 patients globally to between 5000 and 10000 patients is a staggering potential for Egetis and if a potential acquirer knows this and does not have Pareto as an analyst, today's stock prices should be peanuts...... Good evening - tomorrow it continues!
- ·3 päivää sitten · MuokattuMy FB group in the previous post was set as inactive - now it is active. See the previous post with my ChatGPT chat of 54 pages starting in sep’2025 when I bought the first ones. Remember it IS AI - with all the reservations one must have with it. But it does represent a wonderful computing power, which one then just really needs to fact-check and (not least) reality-check!
- ·3 päivää sitten · MuokattuHello - I have an old FB group left over from the happy Corona days - nothing really happens in the group anymore, but now I have just uploaded my 54-page Egetis thread, which starts in September 2025, where I buy the first ones. If you think it's interesting, you can just join - and then just jump out again when you've seen the AI thread. It is generated in a paid ChatGPT - and as always, you should neither use AI nor other people's posts as an investment basis - make your own analyses and ALWAYS fact-check AI answers. I guess I unfortunately can't upload it here - otherwise I would have done it. It is called "Udbytte & Risiko aktier_Balanceret Portefølje"
- ·3 päivää sittenThen we broke 9 on still high volume, extremely bullish! Exciting to see if it opens up for the next round number....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |
2026 Q2 - tulosraportti
45 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenFor those of you who have the energy to read and something we should look out for. For those of you who don't have the energy to read the whole thing can scroll down to my last sentence 😅. This is a small compilation based on ATA, Egetis, et al. if you are interested and it concerns e.g. ATA (stands for American Thyroid Association) and the clinical guidelines that apply to MCT8 deficiency and the use of Tiratricol (Emcitate). When a completely new drug is approved for a rare genetic thyroid disease, it usually happens in the following way in the USA Before a brand new, full-scale "Guideline" has time to be printed, American experts often publish a Consensus Statement or a Clinical Practice Guideline Update in the journal Thyroid. This is done to quickly provide clinicians with guidance on how patients should be screened and dosed. This is one thing we can look out for together. American trade organizations (here ATA is the heaviest player) for both endocrinologists and pharmacists will need to issue guidelines on how lab tests should be interpreted, as tiratricol can interfere with traditional T3 blood tests. Key individuals behind the clinical studies for Emcitate (such as the ReTRIACt study) are prominent American pediatric endocrinologists. These doctors often sit on ATA's committees and push for care to be standardized locally. Emcitate is estimated to be commercially available in the USA within 8 to 10 weeks after approval. Distribution takes place via an exclusive partnership with PANTHERx® Rare, the USA's largest independent specialty pharmacy focused on rare diagnoses. They will handle individualized delivery directly to the families. Emcitate's launch strategy is based on already working closely with pediatric endocrinologists and pediatric neurologists. This means intensive education (Disease Awareness), which in turn usually hurries local hospitals and medical societies to formally write the treatment into their internal care programs. This process is indeed ongoing. What is really interesting here is that Egetis has consciously chosen not to wait for the actual FDA approval to start educating doctors, but has rolled out strategic medical educational efforts in several phases. Egetis has its field team (Medical Science Liaisons – MSLs) fully trained ahead of the launch. They handle the education of staff at hospitals to be trained, regarding dosing and interpretation of lab tests at leading university hospitals and pediatric clinics. They already started two digital platforms last spring. The one directed at patients/families can be viewed here: https://www.lifewithmct8deficiency.com/. Before formal approval in September 2026, tiratricol had already reached over 230 patients in more than 25 countries via so-called Expanded Access Programs (license prescription). Several of the heaviest children's hospitals in the USA have therefore already had patients.. Regarding the future: Epidemiological estimates show that MCT8 deficiency affects approximately 1 in 70,000 boys, meaning that in total there are between 5,000 and 10,000 boys and men in the USA and Europe living with the disease. Since the diagnosis was established as late as 2004, the majority are still undiagnosed, which means Egetis' launch plan has a major focus on finding more of these "hidden" patients via screening at hospitals. Today, over 230 patients are treated globally with Emcitate. The distribution between the USA and the rest of the world looks as follows: Patients in the USA (approx. 50–60 active distributed across Expanded Access Program (EAP): Approximately 40 patients and clinical trials in the ReTRIACt study, approx. 15–19 pieces. From 230 patients globally to between 5000 and 10000 patients is a staggering potential for Egetis and if a potential acquirer knows this and does not have Pareto as an analyst, today's stock prices should be peanuts...... Good evening - tomorrow it continues!
- ·3 päivää sitten · MuokattuMy FB group in the previous post was set as inactive - now it is active. See the previous post with my ChatGPT chat of 54 pages starting in sep’2025 when I bought the first ones. Remember it IS AI - with all the reservations one must have with it. But it does represent a wonderful computing power, which one then just really needs to fact-check and (not least) reality-check!
- ·3 päivää sitten · MuokattuHello - I have an old FB group left over from the happy Corona days - nothing really happens in the group anymore, but now I have just uploaded my 54-page Egetis thread, which starts in September 2025, where I buy the first ones. If you think it's interesting, you can just join - and then just jump out again when you've seen the AI thread. It is generated in a paid ChatGPT - and as always, you should neither use AI nor other people's posts as an investment basis - make your own analyses and ALWAYS fact-check AI answers. I guess I unfortunately can't upload it here - otherwise I would have done it. It is called "Udbytte & Risiko aktier_Balanceret Portefølje"
- ·3 päivää sittenThen we broke 9 on still high volume, extremely bullish! Exciting to see if it opens up for the next round number....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 95 353 | 95 353 | 0 | 0 |